PMEL and uveal melanoma: Tebentafusp’s mechanism involves binding to gp100 on tumor cells and simultaneously engaging the CD3 complex on T cells, thereby redirecting and activating cytotoxic immune responses (9).This dual targeting approach bypasses HLA class I downregulation, a common immune evasion strategy in uveal melanoma (10), and enables a more precise and effective immune attack.